Loading…
Industrial By‐Products As a Novel Circular Source of Biocompatible Extracellular Vesicles
Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by‐products (BP) as a circular sourc...
Saved in:
Published in: | Advanced functional materials 2022-07, Vol.32 (29), p.n/a |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Extracellular vesicles (EVs) constitute an intricate system of molecular exchange that has recently gained tremendous interest. However, sustainable sources of safe biological EVs remain scarce and elusive. This study explores and defines the use of food industry by‐products (BP) as a circular source of safe biocompatible EVs. Averaged diameter and molecular compositions indicate a large yield of exosomes and high abundancy of membrane lipids with signaling capacity in these vesicles. Complex proteomes mimicking those circulating in human blood plasma are also identified. Furthermore, BP‐EVs do not show relevant cytotoxicity and display excellent oral and intravenous bioavailability together with specific organ targeting capacity. Collectively, it is believed that the novel findings reported here will open substantial venues for the use of BP as an optimal source of biocompatible nanovesicles in manifold applications of the biotechnological and biomedical fields.
Extracellular vesicles are identified in food industry by‐products (BP‐EVs). BP‐EVs can be obtained in an industrially scalable manner. Food industry by‐products become an optimal source of nanocarriers. BP‐EVs demonstrate excellent biocompatible and nontoxic features. BP‐EVs demonstrate brain targeting capacity and excellent oral bioavailability. |
---|---|
ISSN: | 1616-301X 1616-3028 |
DOI: | 10.1002/adfm.202202700 |